Wai Conrad sold $879K of CLOV (indirect holdings)
Wai Conrad (CEO, Counterpart Health) sold 220,426 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $3.99 ($0.88M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and total value, plus confirmation that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling optics, but the 10b5-1 designation makes this more of a routine datapoint than a catalyst.
What to watch
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it is less likely to reflect new negative information about near-term prospects.
Background
The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. (CLOV).
Ticker impact
Clover Health CEO Wai Conrad filed a Form 4 selling 220,426 shares at $3.9900 on a 10b5-1 plan, totaling about $879.5K.
Likely minimal immediate impact; any effect is more about sentiment than new company-specific information.
The filing discloses an open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification or tax planning, so the market may overreact to the headline optics.
Key entities
- issuerCLOVER HEALTH INVESTMENTS, CORP. /DE
Company whose Form 4 insider sale was disclosed.
- insiderWai Conrad
CEO, Counterpart Health, reporting an indirect open-market sale under a 10b5-1 plan.
